Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2017 08:00 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting

SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of a poster addressing results with the company’s pan-caspase inhibitor...
October 18, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

SAN DIEGO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the European Medicines Agency (EMA) has granted orphan designation to Conatus’ drug...
August 31, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer

SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
August 29, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus to Present at Rodman & Renshaw Global Investment Conference

SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the...
August 14, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-NF, a randomized, double-blind, placebo-controlled,...
August 02, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates

SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
July 26, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results

SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the second quarter ended June 30, 2017, after the...
July 06, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment

SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that its exclusive license with Novartis for the global development and commercialization of...
June 26, 2017 07:00 ET | Source: Conatus Pharmaceuticals Inc.

FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
June 16, 2017 07:00 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

GALWAY, Ireland, June 16, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that a poster addressing preclinical results with the company’s lead pancaspase...